Kelly Scaggs Campen
Examiner (ID: 2758, Phone: (571)272-6740 , Office: P/3691 )
Most Active Art Unit | 3691 |
Art Unit(s) | 3624, 2165, 2164, 3312, 3738, 3691 |
Total Applications | 1052 |
Issued Applications | 501 |
Pending Applications | 228 |
Abandoned Applications | 322 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 15831947
[patent_doc_number] => 20200131255
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-30
[patent_title] => METHODS OF TREATING NEURODEGENERATIVE DISEASES
[patent_app_type] => utility
[patent_app_number] => 16/576249
[patent_app_country] => US
[patent_app_date] => 2019-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23725
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16576249
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/576249 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | Sep 18, 2019 | Abandoned |
Array
(
[id] => 15683695
[patent_doc_number] => 20200096511
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-26
[patent_title] => SAMPLE DESTRUCTION VALIDATION SYSTEM AND METHODS
[patent_app_type] => utility
[patent_app_number] => 16/576415
[patent_app_country] => US
[patent_app_date] => 2019-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8762
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 72
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16576415
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/576415 | SAMPLE DESTRUCTION VALIDATION SYSTEM AND METHODS | Sep 18, 2019 | Pending |
Array
(
[id] => 16353130
[patent_doc_number] => 10793631
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-10-06
[patent_title] => Human PAC1 antibodies
[patent_app_type] => utility
[patent_app_number] => 16/572271
[patent_app_country] => US
[patent_app_date] => 2019-09-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 39652
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16572271
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/572271 | Human PAC1 antibodies | Sep 15, 2019 | Issued |
Array
(
[id] => 18421600
[patent_doc_number] => 20230176064
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => METHODS AND KITS FOR DETECTING TARGET SUBSTANCES
[patent_app_type] => utility
[patent_app_number] => 17/040821
[patent_app_country] => US
[patent_app_date] => 2019-08-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33724
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17040821
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/040821 | METHODS AND KITS FOR DETECTING TARGET SUBSTANCES | Aug 27, 2019 | Pending |
Array
(
[id] => 18503558
[patent_doc_number] => 11701348
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2023-07-18
[patent_title] => Psilocybin compositions
[patent_app_type] => utility
[patent_app_number] => 16/552498
[patent_app_country] => US
[patent_app_date] => 2019-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5461
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16552498
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/552498 | Psilocybin compositions | Aug 26, 2019 | Issued |
Array
(
[id] => 19211788
[patent_doc_number] => 12000844
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-04
[patent_title] => Diagnostic drug and diagnostic method for Alzheimer's disease
[patent_app_type] => utility
[patent_app_number] => 17/265805
[patent_app_country] => US
[patent_app_date] => 2019-08-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 16
[patent_no_of_words] => 23760
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 306
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17265805
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/265805 | Diagnostic drug and diagnostic method for Alzheimer's disease | Aug 5, 2019 | Issued |
Array
(
[id] => 15435461
[patent_doc_number] => 20200031914
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-30
[patent_title] => ANTIBODIES RECOGNIZING MEDIN
[patent_app_type] => utility
[patent_app_number] => 16/530551
[patent_app_country] => US
[patent_app_date] => 2019-08-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28586
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16530551
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/530551 | ANTIBODIES RECOGNIZING MEDIN | Aug 1, 2019 | Abandoned |
Array
(
[id] => 16564290
[patent_doc_number] => 10889650
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-01-12
[patent_title] => Agent, uses and methods for treatment
[patent_app_type] => utility
[patent_app_number] => 16/521279
[patent_app_country] => US
[patent_app_date] => 2019-07-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 40
[patent_figures_cnt] => 42
[patent_no_of_words] => 28907
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16521279
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/521279 | Agent, uses and methods for treatment | Jul 23, 2019 | Issued |
Array
(
[id] => 18667566
[patent_doc_number] => 11774457
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-03
[patent_title] => Identification and analysis of protein biomarkers
[patent_app_type] => utility
[patent_app_number] => 16/506639
[patent_app_country] => US
[patent_app_date] => 2019-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 60
[patent_figures_cnt] => 106
[patent_no_of_words] => 23746
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 106
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16506639
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/506639 | Identification and analysis of protein biomarkers | Jul 8, 2019 | Issued |
Array
(
[id] => 15432465
[patent_doc_number] => 20200030415
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-30
[patent_title] => COMBINATION THERAPY WITH CGRP ANTAGONISTS AND CLOSTRIDIAL DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 16/503740
[patent_app_country] => US
[patent_app_date] => 2019-07-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11777
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16503740
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/503740 | COMBINATION THERAPY WITH CGRP ANTAGONISTS AND CLOSTRIDIAL DERIVATIVES | Jul 4, 2019 | Abandoned |
Array
(
[id] => 16854937
[patent_doc_number] => 20210155682
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-27
[patent_title] => COMPOSITIONS AND METHODS FOR REDUCTION OF LIPOPROTEIN A FORMATION AND TREATMENT OF AORTIC VALVE SCLEROSIS AND AORTIC STENOSIS
[patent_app_type] => utility
[patent_app_number] => 17/257055
[patent_app_country] => US
[patent_app_date] => 2019-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15600
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 136
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17257055
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/257055 | COMPOSITIONS AND METHODS FOR REDUCTION OF LIPOPROTEIN A FORMATION AND TREATMENT OF AORTIC VALVE SCLEROSIS AND AORTIC STENOSIS | Jun 30, 2019 | Pending |
Array
(
[id] => 18028952
[patent_doc_number] => 11512125
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-29
[patent_title] => Antibodies for the treatment of synucleinopathies and neuroinflammation
[patent_app_type] => utility
[patent_app_number] => 17/255776
[patent_app_country] => US
[patent_app_date] => 2019-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 34
[patent_figures_cnt] => 54
[patent_no_of_words] => 23213
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17255776
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/255776 | Antibodies for the treatment of synucleinopathies and neuroinflammation | Jun 26, 2019 | Issued |
Array
(
[id] => 15963137
[patent_doc_number] => 20200165320
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-28
[patent_title] => IN VITRO GLYCOENGINEERING OF ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 16/447093
[patent_app_country] => US
[patent_app_date] => 2019-06-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18810
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16447093
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/447093 | IN VITRO GLYCOENGINEERING OF ANTIBODIES | Jun 19, 2019 | Abandoned |
Array
(
[id] => 15175459
[patent_doc_number] => 20190358321
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-28
[patent_title] => USE OF SEMAPHORIN-4D BINDING MOLECULES FOR MODULATION OF BLOOD BRAIN BARRIER PERMEABILITY
[patent_app_type] => utility
[patent_app_number] => 16/433496
[patent_app_country] => US
[patent_app_date] => 2019-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21002
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16433496
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/433496 | Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability | Jun 5, 2019 | Issued |
Array
(
[id] => 16389620
[patent_doc_number] => 20200330561
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-22
[patent_title] => COMPOSITION FOR TREATMENT OF FACIAL NERVE PALSY
[patent_app_type] => utility
[patent_app_number] => 16/433797
[patent_app_country] => US
[patent_app_date] => 2019-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3323
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16433797
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/433797 | COMPOSITION FOR TREATMENT OF FACIAL NERVE PALSY | Jun 5, 2019 | Abandoned |
Array
(
[id] => 16290128
[patent_doc_number] => 10766964
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-09-08
[patent_title] => Compositions and methods for treating and preventing inflammation
[patent_app_type] => utility
[patent_app_number] => 16/422273
[patent_app_country] => US
[patent_app_date] => 2019-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 86
[patent_figures_cnt] => 149
[patent_no_of_words] => 29691
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16422273
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/422273 | Compositions and methods for treating and preventing inflammation | May 23, 2019 | Issued |
Array
(
[id] => 16962872
[patent_doc_number] => 20210214371
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-15
[patent_title] => Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates
[patent_app_type] => utility
[patent_app_number] => 17/056270
[patent_app_country] => US
[patent_app_date] => 2019-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19174
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17056270
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/056270 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | May 19, 2019 | Pending |
Array
(
[id] => 15117209
[patent_doc_number] => 20190345237
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-14
[patent_title] => ANTIBODY-BASED THERAPY OF TRANSTHYRETIN (TTR) AMYLOIDOSIS AND HUMAN-DERIVED ANTIBODIES THEREFOR
[patent_app_type] => utility
[patent_app_number] => 16/413335
[patent_app_country] => US
[patent_app_date] => 2019-05-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48120
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16413335
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/413335 | Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor | May 14, 2019 | Issued |
Array
(
[id] => 16727864
[patent_doc_number] => 20210095011
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-01
[patent_title] => IMPROVED ANTI-FIBRONECTIN EDA ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/051804
[patent_app_country] => US
[patent_app_date] => 2019-05-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16879
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17051804
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/051804 | IMPROVED ANTI-FIBRONECTIN EDA ANTIBODIES | Apr 30, 2019 | Abandoned |
Array
(
[id] => 17931132
[patent_doc_number] => 20220326257
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-13
[patent_title] => DETECTION OF AUTOANTIBODIES AGAINST DEIMINATED PROTEIN EPITOPES ASSOCIATED WITH BRAIN OXYGEN DEPRIVATION
[patent_app_type] => utility
[patent_app_number] => 17/051857
[patent_app_country] => US
[patent_app_date] => 2019-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22330
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17051857
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/051857 | DETECTION OF AUTOANTIBODIES AGAINST DEIMINATED PROTEIN EPITOPES ASSOCIATED WITH BRAIN OXYGEN DEPRIVATION | Apr 29, 2019 | Pending |